Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Buy
52
CYCN Quote, Financials, Valuation and Earnings
Last price:
$3.24
Seasonality move
:
-0.35%
Day range:
$2.83 - $3.43
52-week range:
$1.27 - $9.47
Dividend yield:
0%
P/E ratio:
3.20x
P/S ratio:
--
P/B ratio:
1.05x
Volume:
262.9K
Avg. volume:
6.5M
1-year change:
-24.94%
Market cap:
$8.6M
Revenue:
--
EPS (TTM):
-$2.14
Analysts' Opinion
-
Consensus RatingCyclerion Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Cyclerion Therapeutics has an estimated upside of 2407.84% from its current price of $3.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $3.19.
Fair Value
-
According to the consensus of 0 analysts, Cyclerion Therapeutics has 2407.84% upside to fair value with a price target of -- per share.
CYCN vs. S&P 500
-
Over the past 5 trading days, Cyclerion Therapeutics has underperformed the S&P 500 by -5.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cyclerion Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cyclerion Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cyclerion Therapeutics reported revenues of $194K.
Earnings Growth
-
Cyclerion Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cyclerion Therapeutics reported earnings per share of -$0.29.
Enterprise value:
5.8M
EV / Invested capital:
0.70x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.93x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-44.82%
Net Income Margin (TTM):
--
Return On Equity:
-51.71%
Return On Invested Capital:
-51.71%
Operating Margin:
-581.44%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $194K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$45.3M | -$12.3M | -$5.9M | -$2.7M | -$1.1M | |
| EBITDA | -$45.2M | -$12.3M | -$5.9M | -$2.7M | -$1.1M | |
| Diluted EPS | -$21.79 | -$5.63 | -$2.14 | $2.72 | -$0.29 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $70.1M | $63.7M | $21.7M | $9.9M | $3.5M | |
| Total Assets | $131.4M | $67.7M | $25.1M | $15.2M | $8.9M | |
| Current Liabilities | $16.3M | $11.4M | $8.5M | $2.3M | $700K | |
| Total Liabilities | $56M | $11.4M | $8.5M | $2.3M | $700K | |
| Total Equity | $75.4M | $56.4M | $16.5M | $12.9M | $8.2M | |
| Total Debt | $3.5M | $3.5M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$42.2M | -$26.7M | -$6.2M | -$6.9M | -$1.7M | |
| Cash From Investing | -- | -- | -- | $10.4M | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -$42.2M | -$26.7M | -$6.2M | -$6.9M | -$1.7M | |
CYCN
Sector
Market Cap
$8.6M
$44.6M
Price % of 52-Week High
33.69%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-24.94%
-29.09%
Beta (5-Year)
1.875
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$3.31
200-day SMA
Buy
Level
$2.87
Bollinger Bands (100)
Buy
Level
2.13 - 3.49
Chaikin Money Flow
Sell
Level
-68.7M
20-day SMA
Buy
Level
$3.13
Relative Strength Index (RSI14)
Buy
Level
50.98
ADX Line
Buy
Level
7.14
Williams %R
Neutral
Level
-79.4934
50-day SMA
Buy
Level
$2.76
MACD (12, 26)
Buy
Level
0.19
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
215.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Stock Forecast FAQ
In the current month, CYCN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CYCN average analyst price target in the past 3 months is --.
-
Where Will Cyclerion Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cyclerion Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Cyclerion Therapeutics?
Analysts are divided on their view about Cyclerion Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cyclerion Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Cyclerion Therapeutics's Price Target?
The price target for Cyclerion Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CYCN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cyclerion Therapeutics is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CYCN?
You can purchase shares of Cyclerion Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cyclerion Therapeutics shares.
-
What Is The Cyclerion Therapeutics Share Price Today?
Cyclerion Therapeutics was last trading at $3.24 per share. This represents the most recent stock quote for Cyclerion Therapeutics. Yesterday, Cyclerion Therapeutics closed at $3.19 per share.
-
How To Buy Cyclerion Therapeutics Stock Online?
In order to purchase Cyclerion Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
